Relmada Therapeutics Inc (NASDAQ:RLMD) has a beta value of 0.15 and has seen 0.42 million shares traded in the recent trading session. The company, currently valued at $10.79M, closed the recent trade at $0.32 per share which meant it gained $0.03 on the day or 12.15% during that session. The RLMD stock price is -1375.0% off its 52-week high price of $4.72 and 25.0% above the 52-week low of $0.24. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.28 million shares traded. The 3-month trading volume is 908.12K shares.
The consensus among analysts is that Relmada Therapeutics Inc (RLMD) is Sell stock at the moment, with a recommendation rating of 3.00. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
Relmada Therapeutics Inc (NASDAQ:RLMD) trade information
Sporting 12.15% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the RLMD stock price touched $0.32 or saw a rise of 6.02%. Year-to-date, Relmada Therapeutics Inc shares have moved -37.50%, while the 5-day performance has seen it change 9.98%. Over the past 30 days, the shares of Relmada Therapeutics Inc (NASDAQ:RLMD) have changed 7.44%. Short interest in the company has seen 1.62 million shares shorted with days to cover at 4.07.
Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could jump 95.43% from the levels at last check today.. The projected low price target is $2.0 while the price target rests at a high of $8.0. In that case, then, we find that the latest price level in today’s session is -2400.0% off the targeted high while a plunge would see the stock gain -525.0% from the levels at last check today..
Relmada Therapeutics Inc (RLMD) estimates and forecasts
The company’s shares have lost -90.71% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 0.68% over the past 5 years. Earnings growth for 2025 is a modest 34.72% while over the next 5 years, the company’s earnings are expected to increase by 19.94%.
RLMD Dividends
Relmada Therapeutics Inc is expected to release its next earnings report on 2025-Mar-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Relmada Therapeutics Inc (NASDAQ:RLMD)’s Major holders
Insiders own 7.28% of the company shares, while shares held by institutions stand at 27.08% with a share float percentage of 29.20%. Investors are also buoyed by the number of investors in a company, with Relmada Therapeutics Inc having a total of 63.0 institutions that hold shares in the company. The top two institutional holders are DEEP TRACK CAPITAL, LP with over 1.23 million shares worth more than $3.7 million. As of 2024-06-30, DEEP TRACK CAPITAL, LP held 16.3686% of shares outstanding.
The other major institutional holder is VESTAL POINT CAPITAL, LP, with the holding of over 1.2 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.6 million and represent 15.9076% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND . As of Dec 31, 2024 , the former fund manager holds about 8.61% shares in the company for having 851.92 shares of worth $0.27 million while later fund manager owns 456.4 shares of worth $0.15 million as of Jan 31, 2025 , which makes it owner of about 4.61% of company’s outstanding stock.
